EAST BRUNSWICK, N.J., June 22, 2018 /PRNewswire/ -- Grace Therapeutics, a clinical stage biopharmaceutical company focused on rare and orphan diseases, announced today that William Haseltine has been appointed to the company's Board of Directors. Dr. Haseltine is currently Chairman and President of ACCESS Health International, Inc. and Chairman of the Haseltine Foundation for Science and the Arts. He is the Founder of Human Genome Sciences, Inc. and served as its Chairman and CEO for twelve years. He is also the founder of several other successful biotechnology companies. Eight pharmaceutical products from companies that he started are currently approved by US and international regulatory agencies.
"Having spent time with Bill over the past few years, I appreciate and value his broad strategic skills and extensive experience as one of the industry's foremost leaders," said Vimal Kavuru, Co-Founder and Chairman of Grace. "I am delighted to welcome Bill to our Board. Our team looks forward to working closely with him as we develop and commercialize innovative products and build a world class biopharmaceutical company."
"I am honored to serve on Grace's Board of Directors," said Dr. Haseltine, "and am looking forward to helping the Board and management team advance their vision of improving the standard of care for many important, but inadequately treated diseases."
"We are assembling a Board that is expertly positioned to guide us through our rapid growth and promising future by bringing innovative therapeutics that improve patient outcomes," said George Kottayil, PhD, Co-Founder and Chief Executive Officer, Grace Therapeutics. "Bill's unique and remarkable background in cutting-edge research and enterprise building will be invaluable to Grace as we continue to advance our business strategy and address unmet needs across a number of therapeutic areas."
Dr. Haseltine maintains an active and distinguished career in science and business. He is a Founder and CEO of Demetrix, Inc., a biotechnology company specializing in pain and anxiety medications, and a Founder and Director of X-VAX, which is developing a novel Herpes Simplex vaccine. Earlier in his career, he was a professor at Harvard Medical School and Harvard School of Public Health, where he was the Founder and Chair of the Division of Biochemical Pharmacology and the Division of Human Retrovirology. He is well known for his seminal work on cancer, HIV/AIDS and genomics, and has authored more than 200 manuscripts published in peer reviewed journals.
Dr. Haseltine is a Lifetime Governor of the New York Academy of Sciences, a Trustee of the New York Academy of Medicine, and an honorary trustee of the Brookings Institution. He is also the author of several recent books: Affordable Excellence: The Singapore Healthcare Story (2013); Aging with Dignity: Innovation and Challenge in Sweden, the Voice of Healthcare Professionals (2017); ACCESS Health International: Our ten-year journey to improve access to high quality affordable health for all (2017); Every Second Counts; Saving two million lives. The story of Emergency Medical Research Institute of India (2018); Voices in Dementia Care (2018).
About Grace Therapeutics
Grace Therapeutics, Inc. is an innovative biopharmaceutical company focused on rare and orphan diseases. Grace utilizes unique delivery technologies in developing novel product formulations to address critical unmet needs with a strategy that is evidence-based and outcomes-driven.
Grace's development pipeline consists of five product candidates focused primarily on Central Nervous System diseases. Clinical studies are ongoing for three of these late stage assets, with the remaining two advancing toward the clinic. The company is pursuing multiple commercialization options for these products for maximum value creation in its path to becoming a fully integrated commercial and marketing organization.
Headquartered in East Brunswick, New Jersey, privately held Grace has strategic agreements with pre-eminent partners in contract research, manufacturing and market development. To learn more, visit www.gtrx.com.
SOURCE Grace Therapeutics